Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy

Related Clinical Trial
A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN) Study to Assess PXL065 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD) Study to Assess PXL770 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD) Study of Disease Progression in Adults With Inherited Forms of Spastic Paraplegia Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy Modeling Macrophages Activation Pattern in X-linked Adrenoleukodystrophy and Metachromatic Leukodystrophy SMART-ALD – A New Lifestyle Intervention to Improve Quality of Life in Women With X-linked Adrenoleukodystrophy (X-ALD) Quality of Life in Women With X-linked Adrenoleukodystrophy A Clinical Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT) Plasma Exchange With Albumin in AMN Patients Stem Cell Transplant for Inborn Errors of Metabolism Human Placental-Derived Stem Cell Transplantation Precision Exercise in Children With Malignant Hemopathies Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy MD1003-AMN MD1003 in Adrenomyeloneuropathy A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients. Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD) A Clinical Trial for AMN: Validation of Biomarkers of Oxidative Stress, Efficacy and Safety of a Mixture of Antioxidants Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy Repetitive Transcranial Magnetic Stimulation as Therapy in Hereditary Spastic Paraplegia and Adrenomyeloneuropathy Clinical Study and Gene Mutation Analysis of Adrenoleukodystrophy in Taiwanese Children Early Diagnosis Of Childhood Cerebral ALD Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy Multi-center Clinical Study on the Diagnosis and Treatment Management of Rare Neurological Disease in Children HSCT for High Risk Inherited Inborn Errors Longitudinal Natural History Study of Patients With Peroxisome Biogenesis Disorders (PBD) UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD) A Phase III Trial of Lorenzo’s Oil in Adrenomyeloneuropathy Lentiviral Gene Therapy for X-ALD MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD) Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD) Newborn Screening for Adrenoleukodystrophy A Study to Prospectively Assess Disease Progression in Male Children With X-ALD Long-term Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product Exercise Study of Function and Pathology for Women With X-linked Adrenoleukodystrophy Expanded Access for Lorenzo’s Oil (GTO/GTE) in Adrenoleukodystrophy Minnesota Adrenoleukodystrophy Registry Study (MARS) and Biobank A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy Effect of Glycerol Trierucate on Clinical Course of Adrenoleukodystrophy

Brief Title

Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy

Brief Summary

      OBJECTIVES: I. Evaluate the efficacy of interferon beta and thalidomide in male patients with
      adrenoleukodystrophy who show evidence of brain inflammatory response and are receiving
      concurrent glyceryl trierucate and glyceryl trioleate (Lorenzo's oil).

      II. Evaluate the progress of the disease and possible side effects of the medication in these

Detailed Description

      PROTOCOL OUTLINE: This is randomized, double blind, placebo controlled study. Patients are
      randomized to receive beta interferon and thalidomide placebo (arm I), thalidomide and beta
      interferon placebo (arm II), or placebo for both beta interferon and thalidomide (arm III).
      Patients receive interferon beta by subcutaneous injection and thalidomide orally. All
      patients are maintained on glyceryl trierucate and glyceryl trioleate (Lorenzo's oil)

      Patients are followed at 3, 6, and 12 months and then may be followed every 6 months

Study Type





glyceryl trierucate


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

August 1998

Completion Date

November 2000

Eligibility Criteria


        --Disease Characteristics-- Adrenoleukodystrophy (ALD) diagnosis based on history and
        examination, MRI, and biochemical assay

        Clinical evidence of rapidly progressive phase of cerebral ALD must include 2 or more of
        the following during the preceding year:

        Significant and progressive impairment of school performance Significant loss of cognitive
        function leading to an IQ of 75 or less Progressive impairment of the ability to understand
        spoken words Progressive impairment of vision Progressive deterioration of handwriting
        Progressive difficulty in walking Progressive impairment in speech articulation, and
        vocabulary Progressive weakness of one or more limbs

        Must have MRI abnormalities characteristic of cerebral ALD, especially evidence of the
        breakdown of the blood-brain barrier using gadolinium contrast medium and magnetization
        transfer technique Evidence of brain white matter inflammatory response Must not meet
        criteria for bone marrow transplantation Not in an apparent vegetative state
        --Prior/Concurrent Therapy-- Concurrent glyceryl trierucate and glyceryl trioleate
        (Lorenzo's oil) therapy required --Patient Characteristics-- Effective contraception
        required of all patients




4 Years - N/A

Accepts Healthy Volunteers



Hugo Wolfgang Moser, , 

Administrative Informations



Organization ID


Secondary IDs


Study Sponsor

FDA Office of Orphan Products Development


 Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Study Sponsor

Hugo Wolfgang Moser, Study Chair, Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Verification Date

January 2001